We have examined the effect of protein synthesis and of ribosome loading on the estrogen-mediated stabilization of hepatic Xenopus laevis vitellogenin mRNA. Removal of estradiol-17/3 from the culture medium, which destabilizes vitellogenin mRNA, does not alter the density of ribosomes on polysomal vitellogenin mRNA, or change the proportion of vitellogenin mRNA associated with the endoplasmic reticulum. Cycloheximide, which inhibits elongation, without changing the density of ribosomes on vitellogenin mRNA, does not block estrogen-mediated stabilization. In contrast, 2-(4-rrK^yl-2,6KlirutTcanUmo)-N-methylpropionarnide, (MDMP), which inhibits initiation, greatly reduces the density of ribosomes on vitellogenin mRNA, and completely blocks estrogen-mediated stabilization. Vitellogenin mRNA in MDMP treated cells is degraded at a rate similar to that seen when untreated cells are transferred from medium containing estrogen to estrogen-free medium. This suggests that a ribosome-associated degradative system may not be responsible for vitellogenin mRNA degradation. The failure of estrogen to stabilize vitellogenin mRNA in MDMP-treated cells is not due to the release of vitellogenin mRNA from the endoplasmic reticulum. Vitellogenin mRNA in MDMP-treated cells remains associated with the endoplasmic reticulum in small polysomes containing 3-5 ribosomes. These data demonstrate that maintaining a high density of ribosomes on vitellogenin mRNA, but not continuing protein synthesis, is necessary for estrogen-mediated stabilization of vitellogenin mRNA.
INTRODUCTION
The estrogen induction of the hepatic mRNA coding for the egg yolk precursor protein, vitellogenin, in Xenopus laevis is achieved through both activation of vitellogenin gene transcription and by specific stabilization of vitellogenin mRNA against cytoplasmic degradation (1 -3) . In Xenopus liver fragment cultures, vitellogenin mRNA exhibits a half life of approximately 500 hours when estrogen is present and 16 hours at 25° (1), or 30 hours at 20° (see below) following removal of estrogen from the cell culture medium. Since the 16 hour half life (at 25°) of total cell poly(A) mRNA is the same in the presence and absence of estrogen (1) , the stabilization of vitellogenin mRNA is a specific effect of estrogen. Vitellogenin mRNA stabilization is a reversible cytoplasmic effect of a nuclear hormone-receptor complex (1, 4) , and is representative of a number of systems in which hormones regulate the stability of specific mRNAs (reviewed in: 2,3,5,6).
Translation is required for controlling the degradation of histone (7) and tubulin mRNAs (8) (9) (10) . Premature termination of protein synthesis causes the accelerated degradation of triosephosphate isomerase (11) and yeast URA3 and PGK1 mRNAs (12, 13) . Little is known of the role played by protein synthesis and ribosome loading in hormone mediated regulation of mRNA stability. We previously demonstrated that inhibition of protein synthesis with cycloheximide does not prevent the stabilization of vitellogenin mRNA in the presence of estrogen, or its destabilization on removal of estrogen from the culture medium (1) . However, those studies did not determine the distribution of vitellogenin mRNA in polysomes of cycloheximide treated cells. In this work we describe a method of preparing polysomes from Xenopus liver fragment cultures, and its use in studies of the role of protein synthesis and ribosome loading in the stabilization of vitellogenin mRNA. We find that the density of ribosomes on vitellogenin mRNA does not change on removal of estrogen from the culture medium, indicating that destabilization is not caused by a loss of protection by ribosomes, or by release of vitellogenin mRNA from membrane-bound polysomes. Through the use of protein synthesis inhibitors specific for the initiation and elongation steps in protein synthesis, we demonstrate that a high density of ribosomes on vitellogenin mRNA, but not protein synthesis per se, is required for the estrogen-mediated stabilization of vitellogenin mRNA.
EXPERIMENTAL PROCEDURES Polysome isolation
Total polysomes were isolated from Xenopus laevis primary liver fragment cultures. Liver fragment cultures were prepared and maintained as we have described (1) , except that phenol red-free culture medium was used. The tissue was homogenized in 10 vol. of icecold homogenization buffer (HB), (50 mM HEPES, pH 7.8, 200 mM sucrose, 70 mM KC1, 10 mM MgCl 2 , 5 mM NaCl, 4 mM vanadyl ribonucleoside complex [BRL], 1 mM EGTA, 0.2 mg/ml heparin, 1 mM DTT, and 100 units/ml RNasin [Promega Biotech]) using 4 passes of a teflon-glass homogenizer (A.C. Thomas). 10% Triton X-100 was added with gentle mixing to a final concentration of 2%, and the homogenate was centrifuged at 12,000 rpm at 4° C for 3 min. in a Sorvall HB-4 rotor. The lipid layer was removed and 0.01 vol. of 100 mg/ml heparin was added to the supernatant. Polysomes were isolated on a discontinuous sucrose gradient containing 2 ml of 2.5 M sucrose, 3.5 ml of 1.0 M sucrose and 1.0 ml of 0.5 M sucrose in 50 mM HEPES, pH 7.8, 70 mM KC1, 10 mM MgCl 2 and 5 mM NaCl (HKNM Buffer). After sedimentation at 40,000 rpm in an SW41 rotor for 45 min. at 4° C, the polysomes at the 1.0 M/2.5 M sucrose interface were removed with a syringe and centrifuged for 5 min. at 4° in a microcentrifuge to pellet pigment granules. The polysomes were diluted with three volumes of HKNM Buffer to reduce the sucrose concentration, and approximately 1.0 OD260 un 't °f polysomes was loaded ona0.5M-1.5M linear sucrose gradient in HKNM Buffer. After sedimentation at 50,000 rpm for 45 min. at 4° in an SW 55 rotor, the gradients were scanned at 254 run on an ISCo flow monitor to obtain polysome profiles, and fractions were collected for mRNA assays.
Isolation of free and membrane bound polysomes
Free and membrane bound polysomes were isolated by a modification of the method of Ramsey and Steele (14) . Liver fragment cultures were homogenized in 10 vols. of HB, as described above for total polysomes. The homogenate (without Triton) was sedimented at 4° for 2 min. at 1600 rpm in an SW 55 rotor. The speed was then increased to 24,000 rpm, and the sample was sedimented for an additional 16 min.. The lipid layer was removed, and the supernatant, containing free polysomes and mRNP particles, was stored on ice. The pellet from the membrane-bound fraction was resuspended in the original volume of HB, and pelleted a second time using the same centrifugation conditions. The supernatant was discarded, and the pellet was resuspended in the original volume of HB. 10% Triton-X100 was added with gentle mixing, to a final-concentration of 2%. The solution was spun for 5 min. at 4° at 10,000 rpm in an HB-4 rotor and the supernatant, containing the solubilized membrane-bound polysomes was collected. The free and bound polysome fractions were then centrifuged for 20 min. at 4° at 12,000 rpm in an HB-4 rotor. Total RNA was isolated from the supernatants as we have described (15, 16) . Quantitation of mRNA by dot hybridization Fractions from polysome gradients or free and membrane-bound polysomes were phenolchloroform extracted (15) . 1 /xg of phenol-chloroform extracted RNA (15) from each gradient fraction, or from free and membrane-bound polysome preparations, was spotted on to GeneScreen, UV cross-linked, and hybridized to hexamer-primed labeled cDNAs as we have described (16, 17) . The resulting autoradiograms were scanned by laser densitometry. The data were normalized by stripping the blots and and rehybridizing to a /?-actin cDNA clone (17) . Actin mRNA levels are not regulated by estrogen (17) . The data in Figs. 1 and 2 are presented relative to the fraction with the highest mRNA content, which was set equal to 100%.
Determination of the dose-response curves for protein synthesis inhibitors
The extent of inhibition of translation by cycloheximide, (CHX), and by 2-(4-methyl-2,6-dinitroanilino)-N-methylpropionamide (18), (MDMP), was measured in Xenopus laevis primary liver fragment cultures. To determine the extent of inhibition of protein synthesis, liver cubes maintained in phenol red-free F-12 Coon's medium, were exposed to CHX or MDMP for 48 hours, with media changes every 12 hours. After incubation for 6 hours in medium containing 0.1 mCi of [ 3 H]-leucine, the liver fragments were homogenized by 5 strokes of a Thomas teflon-glass homogenizer in 2 ml of 10 mM KH 2 PO 4 , pH 7.2, 150 mM NaCl, 0.01 mg/ml heparin, and 10 mM leucine. The homogenate was sedimented at 10,000 rpm for 20 min. at 2° in an HB-4 rotor. The lipid layer was removed, and 20 fi\ of the supernatant was spotted on Whatman 540 glass fiber filters. The filters were washed 6 X with 10% trichloroacetic acid containing 10 mM leucine, dried and counted. The data is reported as the percentage of protein synthesis relative to untreated liver cultures.
Measurement of vitellogenin mRNA stability
The half-life of vitellogenin mRNA was measured by RNA dot hybridization, and by our pulse-chase technique (1), with the following modifications. DNA was removed from the isolated RNA by two cycles of selective precipitation with 4 M LiCl (16) . Vitellogenin cDNAs were immobilized by denaturating the DNA in base and applying 1 jig of DNA to nitrocellulose (Schleicher and Schuell) in a dot blot manifold. The area containing the DNA was then cut out of the filter, and baked for 2 hours at 80° in a vacuum oven. The filters were stored under vacuum at room temperature prior to use. Hybridizations were at 42° in 0.2 ml of 50% formamide, 5x SSPE (16), 5x Denhardt's solution, 50 mM Na2HPO 4 , pH 7.2, 0.3 mg/ml yeast tRNA, 20 /tg/ml poly(rA). After hybridization, the filters were washed twice at room temperature in 2 X SSPE, 0.1 % SDS, and once at 60°C in 2x SSPE, 0.1% SDS. The filters were rinsed in 2x SSPE (at room temperature), treated at 37°for 30 min. in 2x SSPE with 1 /ig/ml RNase A and 1 unit/ml RNase Tl, then washed 1 x in 2 X SSPE 0.1 % SDS at 45° C. The filters were base hydrolyzed and counted (1) .
Steady-state measurements of the half life of vitellogenin mRNA were obtained by isolating unlabeld RNA from liver fragment cultures, and quantitating vitellogenin mRNA levels by dot hybridization as described above and in (17) . 
RESULTS

The density of ribosomes on vitellogenin mRNA b the same when it is stabilized and when it is undergoing rapid degradation
In order to evaluate the idea that the destabilization of vitellogenin mRNA results from inefficient translation and a low density of ribosomes on the mRNA, we developed methods for the isolation of undegraded polysomes from Xenopus liver fragment cultures. After culturing the liver cubes for 5 days in estrogen-containing medium to fully induce vitellogenin mRNA, the liver cubes were incubated for an additional 48 hours in medium with or without estrogen. This time period was chosen because other studies demonstrated that vitellogenin mRNA degradation begins within 48 hours of the removal of estrogen from the culture medium (see below). Polysomes were isolated and fractionated on sucrose gradients, and the relative amounts of the 5.7 kb vitellogenin mRNA (19) , and a small 1 kb control mRNA encoding the serum retinol binding protein (16) , were determined by RNA dot blot hybridization (16, 17) with cDNA clones. Although the total amount of vitellogenin mRNA in cells maintained in the absence of estrogen is reduced, the polysome profiles from cells maintained in the presence ( Fig. 1 , induced) and absence ( Fig. 1 , withdrawn) of estrogen are virtually identical. These data indicate that removal of estrogen and destabilization of vitellogenin mRNA are not accompanied by a change in the density of ribosome loading on vitellogenin mRNA.
Effect of protein synthesis inhibitors on estrogen stabilization of vitellogenin mRNA
Our observation that the density of ribosomes on vitellogenin mRNA was unchanged when the mRNA was stabilized by estrogen, and when it was being rapidly degraded in the absence of estrogen, raised the question of whether translation and the presence of the mRNA in polysomes were related to vitellogenin mRNA degradation. To determine whether protein synthesis, or the presence of a normal complement of ribosomes on vitellogenin mRNA, were required for vitellogenin mRNA stabilization, we employed two protein synthesis inhibitors, each specific for a different reaction in protein synthesis.
In preliminary experiments dose response curves were established for the protein synthesis inhibitors, cycloheximide and MDMP. This proved necessary because two other widely used protein synthesis inhibitors, purmoycin and pactamycin, proved unsuitable for use in Xenopus cells (data not shown). Polysomes were isolated from liver cultures maintained in levels of cycloheximide and MDMP which inhibited 96% and 89% of protein synthesis respectively. Cycloheximide, which blocks elongation, inhibited protein synthesis, but did not substantially change the number of ribosomes per polysomes (Fig. 2, CHX) , while MDMP, which inhibits initiation (18) , greatly reduces the number of ribosomes per polysome (Fig. 2, MDMP) . The location of vitellogenin and serum retinol binding protein (RBP) mRNAs in the polysomes from cycloheximide and MDMP-treated cells was determined by RNA dot hybridization. Although the size of vitellogenin synthesizing polysomes in estrogen treated liver has not been determined precisely, Berridge et. al. Xenopus liver fragments were cultured in medium containing 10~6 M estradiol-170 for 5 days, and were then maintained either in medium containing 10~6 M estradiol for 48 hours (induced), or in estradiol-free medium (withdrawn). Polysomes were isolated and fractionated and the relative amount of vitellogenin and RBP mRNA in each fraction was determined by dot hybridization as described in Experimental Procedures. The level of vhellogenin or RBP mRNA in the peak fraction was arbitrarily set equal to 100. The histograms show the vitellogenin or RBP RNA levels in the other fractions relative to the peak fraction. The top of the gradients is on the left. Fig. 3. (upper panel) show that a similar estrogen-mediated stabilization of vitellogenin mRNA was observed in control cells maintained in medium containing estrogen (O), and in cells maintained in medium containing estrogen plus cycloheximide (A). In contrast, viteUogenin mRNA in cells maintained in medium containing estrogen and MDMP was not stabilized (Fig. 3, upper panel [•] ) and was degraded at approximately the same rate (t 1/2 approximately 33 hours) as was observed when vitellogenin mRNA is destabilized after removal of estrogen from the culture medium (•). The decline during the first 24 hours has been observed before (1), and is probably caused by our chase procedure, which uses glucosamine to deplete intracellular undine pools.
To confirm the data obtained in the pulse-labeling experiment, we measured the stability of vitellogenin mRNA by dot hybridization. This method accurately measures vitellogenin mRNA degradation, since we have previously demonstrated that removal of estrogen from the culture medium results in the rapid cessation of vitellogenin gene transcription (1, 21) . Since no new vitellogenin mRNA is being synthesized, the rate of vitellogenin mRNA disappearance represents a direct measure of its degradation rate.
The average data from two experiments in which the degradation rate of hybridizable vitellogenin mRNA was determined is shown in Fig. 3 (lower panel) . Vitellogenin mRNA levels have plateaued at a fully induced level at the start of the experiment, and remain at their induced level in cells maintained in medium containing estradiol (O) or estradiol plus cycloheximide (A). In contrast, vitellogenin mRNA is not stabilized by estrogen in the presence of MDMP. (Fig 3. lower panel [•] ). Vitellogenin mRNA in cells maintained in MDMP plus estrogen and in cells maintained in medium lacking estrogen (•) is degraded with a half life of 30-33 hours. These data clearly show that while protein synthesis is not required for stabilization of vitellogenin mRNA, a normal density of ribosomes on the mRNA is a prerequisite for estrogen mediated stabilization. The effect of MDMP on vitellogenin mRNA stabilization is not the result of a generalized toxic effect of the inhibitor, since the dot hybridization data (Fig. 3, lower panel) are normalized to the level of actin mRNA in the samples (see below). The contribution of mRNA stabilization to steady state vitellogenin mRNA levels is so large that even if vitellogenin gene transcription proceeds at a normal rate in cells maintained in MDMP plus estradiol, destabilization of the mRNA following addition of MDMP will result in a rate of decline in vitellogenin mRNA levels which is virtually indistinguishable from that seen in the absence of estrogen, when there is no detectable vitellogenin transcription 2 . Fig. 2 . MDMP decreases the size of vitellogenin polysomes. Liver fragment cultures were incubated for 5 days in medium containing 10~6 M estradiol-17/3, followed by 48 hours in medium containing 10~6 M estradiol plus either 1 jig/ml cycloheximide (CHX) or 10 #ig/ml MDMP (MDMP). Polysome preparation, RNA isolation and dot hybridization were performed as described in Experimental Procedures and the legend to Fig. 1 . 
Destabilization of vitellogenin mRNA does not entail dissociation from membrane-bound polysomes
Vitellogenin is a secreted protein, and is normally synthesized on membrane-bound polysomes. To investigate the possibility that dissociation from membrane-bound polysomes destabilizes vitellogenin mRNA by rendering it susceptible to normal cellular mRNA degrading systems, we examined the distribution of vitellogenin mRNA in free and membrane-bound polysomes. Dissociation from membrane-bound polysomes might result from a failure to translate vitellogenin mRNA following estrogen withdrawal or MDMP treatment, or from tranlsation of vitellogenin mRNA on free polysomes. RBP mRNA, which encodes the secreted serum retinol binding protein (16) , whose stability is not regulated by estradiol (L. Gould and D. Shapiro, unpublished observations) was used as a control. The data of Table I demonstrate that the proportion of vitellogenin and RBP mRNAs in the free and membrane-bound fractions did not change on estrogen withdrawal, cycloheximide or MDMP treatment. Since the free polysome fraction contains both soluble Free and membrane-bound polysomes were isolated, RNA was extracted and quantitated by dot hybridization as described in Experimental Procedures. The free polysome fraction contains both soluble polysomes and mRNP particles. The total densitometry units for each sample (free + bound) was set equal to 100. The relative amount of each RNA in the free and bound fractions was determined. The -Estrogen sample was induced in estrogen for 5 days and then maintained in estrogen-free medium for 48 hours. At that time vitellogenin mRNA has been destabilized and is undergoing degradation (Fig. 3 ).
polysomes and untranslated non-polysomal mRNA, we conclude that destabilization of vitellogenin mRNA following estrogen withdrawal or MDMP treatment does not result from dissociation of vitellogenin synthesizing polysomes from the endoplasmic reticulum, or from a failure to translate vitellogenin mRNA. Our finding that vitellogenin mRNA in MDMP treated cells is localized on membrane-bound polysomes is consistent with our observation that vitellogenin mRNA in MDMP treated cells, is localized on polysomes containing 3-5 ribosomes (Fig. 2) . This is approximately the size of RBP synthesizing polysomes and is clearly sufficient to allow association of the RBP mRNA with the endoplasmic reticulum (Table 1) .
DISCUSSION
Destabilization of vitellogenin mRNA in the absence of estrogen does not result from a change in ribosome loading
Studies in a number of systems indicate that a decrease in the density of ribosomes on an mRNA accelerates its degradation (11) (12) (13) . However, Cochrane and Deeley (22) compared polysome profiles from estrogen stimulated and withdrawn avian liver, and concluded that the destabilization of apo VLDLII mRNA following estrogen withdrawal is not caused by a change in translational efficiency. We therefore investigated whether the dramatic decrease in vitellogenin mRNA stability, which occurs on removal of estrogen from the culture medium, is due to a change in ribosome loading. Polysomes were isolated from liver fragment cultures after preinducing the cultures with estrogen, and then maintaining the cultures in medium either containing or lacking estrogen. The data of Fig.  1 clearly show that there is no change in the location of vitellogenin mRNA in the polysomes. Thus, destabilization of vitellogenin mRNA in the absence of estrogen does not appear to result from a change in polysome size and ribosome loading. The related possiblity that destabilization of vitellogenin mRNA results from a failure to translate the mRNA, and its release from membrane-bound polysomes to the cytosol, was shown to be incorrect by our data indicating that there is no change in the ratio of membrane-bound polysomal vitellogenin mRNA to free vitellogenin mRNA (Table 1) . Under our conditions, the 'free' fraction includes both soluble polysomal vitellogenin mRNA, and untranslated vitellogenin mRNA in mRNP particles.
A high density of ribosomes on the mRNA, but not protein synthesis, is required for estrogenmediated stabilization of vitellogenin mRNA
In order to determine whether or not translation and ribosome loading were in any way related to vitellogenin mRNA stabilization and degradation, we employed the protein synthesis inhibitors cycloheximide and MDMP, which are specific for the translocation and initiation steps of protein synthesis, respectively. Polysome structure was maintained in cycloheximide (Fig. 2, CHX) . In liver cubes incubated in estrogen plus a level of cycloheximide which inhibits >95% of cell protein synthesis (Fig. 3, [A] ), vitellogenin mRNA was stabilized, confirming and extending our earlier observation (1) . MDMP inihibited protein synthesis approximately 90% under our conditions, resulting in the loading of vitellogenin mRNA with 3-5 ribosomes (Fig. 2, MDMP) . Inhibition of protein synthesis with MDMP completely blocked the estrogen-mediated stabilization of vitellogenin mRNA. Vitellogenin mRNA exhibited a similar half life of approximately 30 hours in liver cultures maintained in MDMP plus estradiol (Fig. 3, [•] and in liver cultures transferred to medium lacking estradiol (Fig. 3, [ • ] ). The data are similar when vitellogenin mRNA degradation is measured by two independent methods; (a) a pulsechase technique (Fig. 3. upper panel) , or (b) by hybridization to quantitate the level of cellular vitellogenin mRNA (Fig. 3, lower panel) .
Several types of evidence indicate that the ability of MDMP to block the estrogen-mediated stabilization of vitellogenin mRNA is due to a specific effect of this protein synthesis inhibitor on vitellogenin mRNA stabilization, and not to a generalized toxic effect. (A) The dot hybridization data of Fig. 3 (lower panel) were normalized to a constant level of actin mRNA in each sample. A generalized toxic effect of the inhibitor on mRNA stability would probably affect both actin and vitellogenin mRNAs, and the normalized vitellogenin mRNA level would probably not change dramatically. What we actually observe is that the actin mRNA level in MDMP-treated cells remains relatively constant throughout the experiment, while vitellogenin mRNA levels decline steadily. In the set of samples which was used in one of the dot hybridizations (Fig. 3, lower panel) , and in the pulse-chase experiment (Fig. 3, upper panel) , actin mRNA levels in samples from MDMP-treated cultures declined only 8% between 24 and 96 hours, while vitellogenin mRNA levels declined 94%. (B) Despite the striking difference in their effects on vitellogenin mRNA stability, the yield of RNA/gram of liver tissue was similar in the cycloheximide and MDMP-treated cultures. (C) Hepatic vitellogenin mRNA exhibits a similar half life of approximately 30 hours after removal of estrogen from the culture medium (Fig. 3, upper and lower panels, [ • ] ) and in cultures maintained in MDMP plus estrogen (Fig. 3, upper and lower panels, [•] ). It seems improbable that a generalized toxic effect of the inhibitor would cause vitellogenin mRNA to be degraded at its normal unstabilized rate. The half life of vitellogenin mRNA in MDMP-treated samples is similar whether it is measured by dot hybridization (Fig.  3, lower panel) , with the data corrected for the decay of cellular actin mRNA, or by a pulse-chase technique (Fig. 3, upper panel) , in which the data is uncorrected. It is highly improbable that a generalized toxic effect of the inhibitor would yield the same half life by these two methods. These data provide strong support for the view that the failure of estrogen to stabilize vitellogenin mRNA in MDMP-treated cells is a specific effect of MDMP on vitellogenin mRNA stability. Since both MDMP and cycloheximide efficiently inhibit protein synthesis under our conditions, the failure of estrogen to stabilize vitellogenin mRNA in MDMP-treated cells is probably due to the greatly reduced density of ribosomes on vitellogenin mRNA (Fig. 2, MDMP) .
Although clearly necessary for stabilization, a high density of ribosomes on vitellogenin mRNA is not sufficient to stabilize the mRNA. Destabilization of vitellogenin mRNA in the absence of estrogen is not accompanied by a change in the density of ribosomes on the mRNA (Fig. 1) . Cycloheximide, which maintains the density of ribosomes on the mRNA while it blocks protein synthesis, does not block the destabilization of vitellogenin mRNA on removal of estrogen from the culture medium (1) .
While these data provide the first evidence for a requirement for normal ribosome loading in the regulation of mRNA stability by steroid hormones, there are several systems in which mRNA stability has been shown to be altered by changes in protein synthesis and ribosome loading. Tubulin mRNA degradation in the presence of excess tubulin monomers requires the mRNA to be in a poly some, and is enhanced in the presence of cycloheximide (8) (9) (10) . Although the nascent polypeptide chain appears to play a key role in the degradation of tubulin mRNA, this is unlikely to be true for vitellogenin, which is a secreted protein.
Histone mRNA can only be selectively degraded when ribosomes are located within 300 nucleotides of a stem and loop structure, which is the probable site of initial cleavage by the ribosome-associated nuclease responsible for its degradation (6, 7, 23, 24) . The absence of ribosomes on histone mRNA results in a failure to degrade it. In contrast, we find that inhibition of protein synthesis by MDMP, which greatly reduces the density of ribosomes on vitellogenin mRNA, results in the degradation of vitellogenin mRNA at a rate similar to that seen for polysomal vitellogenin mRNA in the absence of estrogen (Fig. 3) . Our observation that vitellogenin mRNA exhibits the same half life following estrogen withdrawal when the mRNA is on polysomes containing 30-35 ribosomes (Fig. 1,  withdrawn) , and after MDMP-treatment, when the mRNA is on polysomes containing 3-5 ribosomes (Fig. 2, MDMP) suggests that a ribosome-associated nuclease is probably not respsonsible for vitellogenin mRNA degradation. Since there are still some ribosomes associated with vitellgoenin mRNA in MDMP-treated cells, it remains formally possible that a ribosome-associated degradative system, which degrades the mRNA at the same rate independent of the number of ribosomes on the mRNA, plays a role in vitellogenin mRNA degradation.
Several reports have shown that termination of protein synthesis destabilizes mRNAs. mRNAs destablized by termination include triosephosphate isomerase (11) , and the yeast URA3 and PGK1 gene products (12, 13) . These investigators suggest that the ability of a ribosome to traverse the mRNA and to either impart a specific structure to the mRNP particle, or to physically approach a specific 3' site on the mRNA may be important in controlling mRNA degradation (11) . In the vitellogenin system, the sparse distribution of ribosomes over the entire length of vitellogenin mRNA following inhibition of initiation by approximately 90% in the presence of MDMP is apparently insufficient to allow estrogen to elicit the stabilization of vitellogenin mRNA.
These data identify a new component in the system responsible for the estrogen-mediated stabilization of vitellogenin mRNA. Although ongoing protein syntheisis is not required, stabilization of vitellogenin mRNA requires both estrogen and a full complement of ribosomes on the mRNA. (Fig. 3) , 29,000 molecules will be left after 24 hours if vitellogenin transcription stops, and a quite similar 33,000 molecules will be left if RNA synthesis continues at the normal rate of 4,000 molecules/day.
